☆ 4.7 Letter

CBL mutations in juvenile myelomonocytic leukemia and pediatric myelodysplastic syndrome

LEUKEMIA (2010)

Journal

LEUKEMIA

Volume 24, Issue 5, Pages 1090-1092

Publisher

NATURE PUBLISHING GROUP

DOI: 10.1038/leu.2010.49

Keywords

-

Categories

Oncology Hematology

Funding

Grants-in-Aid for Scientific Research [22659196, 22591171, 21390316] Funding Source: KAKEN

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Oncology

International Consensus Definition of DNA Methylation Subgroups in Juvenile Myelomonocytic Leukemia

Maximilian Schoenung, Julia Meyer, Peter Noellke, Adam B. Olshen, Mark Hartmann, Norihiro Murakami, Manabu Wakamatsu, Yusuke Okuno, Christoph Plass, Mignon L. Loh, Charlotte M. Niemeyer, Hideki Muramatsu, Christian Flotho, Elliot Stieglitz, Daniel B. Lipka

Summary: DNA methylation patterns in JMML can serve as a biomarker for patient stratification. This study established three DNA methylation subgroups and developed a classifier with 98% accuracy, which can classify patients across different technological platforms to guide clinical treatment decisions.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Article Immunology

Heterogeneous disease-propagating stem cells in juvenile myelomonocytic leukemia

Eleni Louka, Benjamin Povinelli, Alba Rodriguez-Meira, Gemma Buck, Wei Xiong, Guanlin Wang, Nikolaos Sousos, Neil Ashley, Angela Hamblin, Christopher A. G. Booth, Anindita Roy, Natalina Elliott, Deena Iskander, Josu de la Fuente, Nicholas Fordham, Sorcha O'Byrne, Sarah Inglott, Ruggiero Norfo, Mariolina Salio, Supat Thongjuea, Anupama Rao, Irene Roberts, Adam J. Mead

Summary: Juvenile myelomonocytic leukemia (JMML) is a childhood leukemia with poor prognosis caused by RAS-pathway mutations. The cellular hierarchy of JMML is complex, with LSCs present in HSPCs, providing new avenues for monitoring and treating the disease.

JOURNAL OF EXPERIMENTAL MEDICINE (2021)

Add to Collection

Article Cell Biology

CircRNAs Dysregulated in Juvenile Myelomonocytic Leukemia: CircMCTP1 Stands Out

Anna Dal Molin, Mattias Hofmans, Enrico Gaffo, Alessia Buratin, Helene Cave, Christian Flotho, Valerie de Haas, Charlotte M. Niemeyer, Jan Stary, Pieter Van Vlierberghe, Jan Philippe, Barbara De Moerloose, Geertruij te Kronnie, Silvia Bresolin, Tim Lammens, Stefania Bortoluzzi

Summary: JMML is characterized by clonal growth of RAS signaling addicted stem cells, with specific mutations defining subtypes and distinct gene, miRNA, and long non-coding RNA expression profiles. This study focused on circRNAs, identifying dysregulated circRNAs and showing expression differences among molecular subgroups of JMML. Validation in an independent cohort confirmed up-regulation of circMCTP1 and its connection to tumor suppressor miRNAs, linking dysregulated circRNAs to regulatory networks.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)

Add to Collection

Review Oncology

Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Jan Philipp Bewersdorf, Amer M. Zeidan

Summary: MDS and CMML are two distinct blood cancers with variable symptoms and risks. Management decisions should be individualized and based on validated risk stratification tools. Supportive care is the mainstay for lower-risk patients, while bone marrow transplant is the only curative option for higher-risk patients.

CANCERS (2021)

Add to Collection

Article Biotechnology & Applied Microbiology

Potential clinical use of azacitidine and MEK inhibitor combination therapy in PTPN11- mutated juvenile myelomonocytic leukemia

Santhosh Kumar Pasupuleti, Karen Chao, Baskar Ramdas, Rahul Kanumuri, Lakshmi Reddy Palam, Sheng Liu, Jun Wan, Colleen Annesley, Mignon L. Loh, Elliot Stieglitz, Michael J. Burke, Reuben Kapur

Summary: Juvenile myelomonocytic leukemia (JMML) is a rare childhood disease characterized by hyperactivation of the Ras/MAPK pathway. Current treatment strategies for JMML, such as the use of hypomethylating agents or MEK inhibitors, are not curative as monotherapy. In this study, a combination treatment of 5-Aza and PD-901 was found to improve hematologic abnormalities and reduce leukemic cells in a murine model of JMML. Furthermore, this combination treatment also showed clinical response in two JMML patients with PTPN11 mutations.

MOLECULAR THERAPY (2023)

Add to Collection

Review Oncology

Genomic and Epigenomic Landscape of Juvenile Myelomonocytic Leukemia

Claudia Finana, Noel Gomez-Molina, Sandra Alonso-Moreno, Laura Belver

Summary: Juvenile myelomonocytic leukemia (JMML) is a rare childhood blood cancer characterized by RAS signaling hyperactivation and genetic and epigenetic alterations. The recent international consensus on JMML stratification has classified the disease into three clinical groups based on DNA methylation status. However, our understanding of JMML origin, cell identity, and heterogeneity remains limited.

CANCERS (2022)

Add to Collection

Article Immunology

Myeloid Clonal Infiltrate Identified With Next-Generation Sequencing in Skin Lesions Associated With Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: A Case Series

Gregoire Martin de Fremont, Pierre Hirsch, Santiago Gimenez de Mestral, Philippe Moguelet, Yoan Ditchi, Jean-Francois Emile, Patricia Senet, Sophie Georgin-Lavialle, Thomas Hanslik, Francois Maurier, Amir Adedjouma, Noemie Abisror, Thibault Mahevas, Florent Malard, Lionel Ades, Pierre Fenaux, Olivier Fain, Francois Chasset, Arsene Mekinian

Summary: In most cases of MDS/CMML, skin lesions are characterized by a clonal myeloid infiltrate, and there is generally a similar mutational profile between blood/bone marrow and skin.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Review Medicine, General & Internal

Current Treatment of Juvenile Myelomonocytic Leukemia

Christina Mayerhofer, Charlotte M. Niemeyer, Christian Flotho

Summary: JMML is a rare pediatric leukemia characterized by mutations in RAS pathway genes, with treatment options based on genetic profile and disease severity. Management can include medication or allogeneic hematopoietic stem cell transplantation tailored to individual patient needs.

JOURNAL OF CLINICAL MEDICINE (2021)

Add to Collection

Review Hematology

Juvenile myelomonocytic leukemia in the molecular era: a clinician's guide to diagnosis, risk stratification, and treatment

Astrid Wintering, Christopher C. Dvorak, Elliot Stieglitz, Mignon L. Loh

Summary: Juvenile myelomonocytic leukemia is a complex disease with diverse clinical outcomes, ranging from spontaneous resolution to transformation to acute myeloid leukemia. Next-generation sequencing allows for more accurate molecular diagnoses, but curative treatment still relies on allogeneic hematopoietic cell transplantation for most patients. Further advances are needed to improve risk stratification algorithms for better management of the disease.

BLOOD ADVANCES (2021)

Add to Collection

Article Oncology

BH3 mimetics and azacitidine show synergistic effects on juvenile myelomonocytic leukemia

Ying Wu, Patricia M. A. Zehnle, Jovana Rajak, Naile Koleci, Geoffroy Andrieux, Lorena Gallego-Villar, Konrad Aumann, Melanie Boerries, Charlotte M. Niemeyer, Christian Flotho, Sheila Bohler, Miriam Erlacher

Summary: JMML cells rely on both MCL-1 and BCL-XL for survival, and azacitidine and BH3 mimetic drugs can effectively target these proteins. Azacitidine acts in vivo through downregulation of MCL-1 and upregulation of BH3-only. Combination treatment of azacitidine with BCL-XL inhibition is more effective in eliminating JMML cells compared to BCL-2 inhibition. These findings highlight the need for clinically applicable MCL-1 or BCL-XL inhibitors in JMML refractory to standard therapy.

LEUKEMIA (2023)

Add to Collection

Letter Oncology

Utility of indium-111 platelet scintigraphy for understanding the mechanism of thrombocytopenia associated with myelodysplastic syndromes and chronic myelomonocytic leukemia

Pauline Durand, Valerie Pottier, Charles Mesguich, Frederic Debordeaux, Estibaliz Lazaro, Jean-Francois Viallard, Etienne Riviere

Summary: This study analyzed the utility of indium-111 platelet scintigraphy (IPS) to better understand the mechanisms and guide treatment of thrombocytopenia in patients with myelodysplastic syndromes (MDS). The results showed that IPS can be a useful tool to identify and treat the increased bleeding risk caused by thrombocytopenia in MDS patients.

EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2023)

Add to Collection

Article Oncology

Mitochondrial Fragmentation Triggers Ineffective Hematopoiesis in Myelodysplastic Syndromes

Yasushige Aoyagi, Yoshihiro Hayashi, Yuka Harada, Kwangmin Choi, Natsumi Matsunuma, Daichi Sadato, Yuki Maemoto, Akihiro Ito, Shigeru Yanagi, Daniel T. Starczynowski, Hironori Harada

Summary: We demonstrated that excessive mitochondrial fragmentation is a fundamental pathobiological phenomenon that could trigger dysplasia formation and ineffective hematopoiesis in MDS. Our findings provide mechanistic insights into ineffective hematopoiesis and suggest dysregulated mitochondrial dynamics as a therapeutic target for treating MDS.

CANCER DISCOVERY (2022)

Add to Collection

Article Multidisciplinary Sciences

Long non-coding RNAs as novel therapeutic targets in juvenile myelomonocytic leukemia

Mattias Hofmans, Tim Lammens, Barbara Depreter, Ying Wu, Miriam Erlacher, Aurelie Caye, Helene Cav, Christian Flotho, Valerie de Haas, Charlotte M. Niemeyer, Jan Stary, Filip Van Nieuwerburgh, Dieter Deforce, Wouter Van Loocke, Pieter Van Vlierberghe, Jan Philipp, Barbara De Moerloose

Summary: In this study, targeting overexpressed long non-coding RNAs (lncRNAs) in JMML was investigated as a therapeutic strategy. Knockdown of three lncRNAs (lnc-THADA-4, lnc-ACOT9-1, and NRIR) resulted in a significant decrease in cell viability in primary JMML cell cultures, with cellular damage correlating with the expression level of the lncRNA of interest. This study suggests that targeting overexpressed lncRNAs may be a viable therapeutic approach for JMML.

SCIENTIFIC REPORTS (2021)

Add to Collection

Article Oncology

Juvenile myelomonocytic leukemia and pediatric myelodysplastic syndromes

Marion Strullu, Thierry Leblanc, Elodie Lainey

Summary: JMML and MDS in children are rare and aggressive diseases, often associated with underlying predisposition syndromes. Accurate clinical examination and molecular analysis can help identify the causes, predict prognosis, and determine the best treatment options for these two diseases.

BULLETIN DU CANCER (2023)

Add to Collection

Review Pathology

The International Consensus Classification (ICC) of hematologic neoplasms with germline predisposition, pediatric myelodysplastic syndrome, and juvenile myelomonocytic leukemia

Martina Rudelius, Olga K. Weinberg, Charlotte M. Niemeyer, Akiko Shimamura, Katherine R. Calvo

Summary: The classification of hematologic neoplasia is critical for diagnosis, therapy, research, and clinical trials. This review summarizes recent advances in the classification of myeloid and lymphoblastic neoplasia with germline predisposition, providing important genetic and phenotypic information, relevant laboratory testing, and pathological bone marrow features. It also focuses on the updated classification of pediatric myelodysplastic syndrome and juvenile myelomonocytic leukemia, highlighting the genetic definitions and distinguishing features.

VIRCHOWS ARCHIV (2023)

Add to Collection

Article Oncology

A Cryptic NUP214-ABL1 Fusion in B-cell Precursor Acute Lymphoblastic Leukemia

Shin-ichi Tsujimoto, Yoshiko Nakano, Tomoo Osumi, Keiko Okada, Meri Ouchi-Uchiyama, Keisuke Kataoka, Yoichi Fujii, Kentaro Ohki, Masafumi Seki, Nobuyoshi Tamagawa, Junko Takita, Seishi Ogawa, Nobutaka Kiyokawa, Junichi Hara, Motohiro Kato

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2018)

Add to Collection

Article Hematology

Preclinical evaluation of NUDT15-guided thiopurine therapy and its effects on toxicity and antileukemic efficacy

Rina Nishii, Takaya Moriyama, Laura J. Janke, Wenjian Yang, Chase C. Suiter, Ting-Nien Lin, Lie Li, Kentaro Kihira, Hidemi Toyoda, Ute Hofmann, Matthias Schwab, Masatoshi Takagi, Tomohiro Morio, Atsushi Manabe, Shirley Kham, Nan Jiang, Karen R. Rabin, Motohiro Kato, Katsuyoshi Koh, Allen Eng-Juh Yeoh, Hiroki Hori, Jun J. Yang

BLOOD (2018)

Add to Collection

Article Biophysics

Impact of graft-versus-host disease on relapse and survival after allogeneic stem cell transplantation for pediatric leukemia

Motohiro Kato, Mio Kurata, Junya Kanda, Koji Kato, Daisuke Tomizawa, Kazuko Kudo, Nao Yoshida, Kenichiro Watanabe, Hiroyuki Shimada, Jiro Inagaki, Katsuyoshi Koh, Hiroaki Goto, Keisuke Kato, Yuko Cho, Yuki Yuza, Atsushi Ogawa, Keiko Okada, Masami Inoue, Yoshiko Hashii, Takanori Teshima, Makoto Murata, Yoshiko Atsuta

BONE MARROW TRANSPLANTATION (2019)

Add to Collection

Letter Biophysics

A prospective study of allogeneic transplantation from unrelated donors for chronic granulomatous disease with target busulfan-based reduced-intensity conditioning

Tomoo Osumi, Daisuke Tomizawa, Toshinao Kawai, Mayumi Sako, Eisuke Inoue, Tetsuya Takimoto, Eiichiro Tamura, Toru Uchiyama, Ken-Ichi Imadome, Maki Taniguchi, Ryota Shirai, Masanori Yoshida, Rie Ando, Yusuke Tsumura, Hiroshi Fuji, Kana Matsumoto, Yoko Shioda, Chikako Kiyotani, Keita Terashima, Masafumi Onodera, Kimikazu Matsumoto, Motohiro Kato

BONE MARROW TRANSPLANTATION (2019)

Add to Collection

Article Biophysics

Allogeneic hematopoietic stem cell transplantation for children and adolescents with high-risk cytogenetic AML: distinctly poor outcomes of FUS-ERG-positive cases

Daisuke Tomizawa, Masanori Yoshida, Tadakazu Kondo, Takako Miyamura, Takashi Taga, Souichi Adachi, Katsuyoshi Koh, Maiko Noguchi, Harumi Kakuda, Kenichiro Watanabe, Yuko Cho, Takahiro Fukuda, Motohiro Kato, Norio Shiba, Hiroaki Goto, Keiko Okada, Masami Inoue, Yoshiko Hashii, Yoshiko Atsuta, Hiroyuki Ishida

BONE MARROW TRANSPLANTATION (2019)

Add to Collection

Article Oncology

Recurrent RARB Translocations in Acute Promyelocytic Leukemia Lacking RARA Translocation

Tomoo Osumi, Shin-ichi Tsujimoto, Moe Tamura, Meri Uchiyama, Kazuhiko Nakabayashi, Kohji Okamura, Masanori Yoshida, Daisuke Tomizawa, Akihiro Watanabe, Hiroyuki Takahashi, Tsukasa Hori, Shohei Yamamoto, Kazuko Hamamoto, Masahiro Migita, Hiroko Ogata-Kawata, Toru Uchiyama, Hiroe Kizawa, Hitomi Ueno-Yokohata, Ryota Shirai, Masafumi Seki, Kentaro Ohki, Junko Takita, Takeshi Inukai, Seishi Ogawa, Toshio Kitamura, Kimikazu Matsumoto, Kenichiro Hata, Nobutaka Kiyokawa, Susumu Goyama, Motohiro Kato

CANCER RESEARCH (2018)

Add to Collection

Article Hematology

Treatment outcome of children with acute lymphoblastic leukemia: the Tokyo Children's Cancer Study Group (TCCSG) Study L04-16

Hiroyuki Takahashi, Ryosuke Kajiwara, Motohiro Kato, Daisuke Hasegawa, Daisuke Tomizawa, Yasushi Noguchi, Kazutoshi Koike, Daisuke Toyama, Hiromasa Yabe, Michiko Kajiwara, Junya Fujimura, Manabu Sotomatsu, Setsuo Ota, Miho Maeda, Hiroaki Goto, Yoko Kato, Tetsuya Mori, Takeshi Inukai, Hiroyuki Shimada, Keitaro Fukushima, Chitose Ogawa, Atsushi Makimoto, Takashi Fukushima, Kentaro Ohki, Katsuyoshi Koh, Nobutaka Kiyokawa, Atsushi Manabe, Akira Ohara

INTERNATIONAL JOURNAL OF HEMATOLOGY (2018)

Add to Collection

Article Allergy

Hematopoietic stem cell transplantation for progressive combined immunodeficiency and lymphoproliferation in patients with activated phosphatidylinositol-3-OH kinase δ syndrome type 1

Tsubasa Okano, Kohsuke Imai, Yuki Tsujita, Noriko Mitsuiki, Kenichi Yoshida, Chikako Kamae, Kenichi Honma, Kanako Mitsui-Sekinaka, Yujin Sekinaka, Tamaki Kato, Katsuyuki Hanabusa, Eri Endo, Takehiro Takashima, Haruka Hiroki, Tzu-Wen Yeh, Keisuke Tanaka, Masakazu Nagahori, Ikuya Tsuge, Yuki Bando, Fuminori Iwasaki, Yoshiaki Shikama, Masami Inoue, Tomiko Kimoto, Naohiko Moriguchi, Yuki Yuza, Takashi Kaneko, Kyoko Suzuki, Tomoyo Matsubara, Yoshihiro Maruo, Tomoaki Kunitsu, Tomoko Waragai, Hideki Sano, Yuko Hashimoto, Kazuhiro Tasaki, Osamu Suzuki, Toshihiko Shirakawa, Motohiro Kato, Toru Uchiyama, Masataka Ishimura, Tetsuzo Tauchi, Hiroshi Yagasaki, Shiann-Tarng Jou, Hsin-Hui Yu, Hirokazu Kanegane, Sven Kracker, Anne Durandy, Daiei Kojima, Hideki Muramatsu, Taizo Wada, Yuzaburo Inoue, Hidetoshi Takada, Seiji Kojima, Seishi Ogawa, Osamu Ohara, Shigeaki Nonoyama, Tomohiro Morio

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2019)

Add to Collection

Article Oncology

Diplotype analysis of NUDT15 variants and 6-mercaptopurine sensitivity in pediatric lymphoid neoplasms

Shinichi Tsujimoto, Tomoo Osumi, Meri Uchiyama, Ryota Shirai, Takaya Moriyama, Rina Nishii, Yuji Yamada, Ko Kudo, Masahiro Sekiguchi, Yuki Arakawa, Masanori Yoshida, Toru Uchiyama, Kiminori Terui, Shuichi Ito, Katsuyoshi Koh, Junko Takita, Etsuro Ito, Daisuke Tomizawa, Atsushi Manabe, Nobutaka Kiyokawa, Jun J. Yang, Motohiro Kato

LEUKEMIA (2018)

Add to Collection

Article Multidisciplinary Sciences

Clonal evolution mechanisms in NT5C2 mutant/relapsed acute lymphoblastic leukaemia

Gannie Tzoneva, Chelsea L. Dieck, Koichi Oshima, Alberto Ambesi-Impiombato, Marta Sanchez-Martin, Chioma J. Madubata, Hossein Khiabanian, Jiangyan Yu, Esme Waanders, Ilaria Iacobucci, Maria Luisa Sulis, Motohiro Kato, Katsuyoshi Koh, Maddalena Paganin, Giuseppe Basso, Julie M. Gastier-Foster, Mignon L. Loh, Renate Kirschner-Schwabe, Charles G. Mullighan, Raul R. Abadan, Adolfo A. Ferrando

NATURE (2018)

Add to Collection

Letter Oncology

Somatic MECOM mosaicism in a patient with congenital bone marrow failure without a radial abnormality

Tomoo Osumi, Shin-ichi Tsujimoto, Kazuhiko Nakabayashi, Maki Taniguchi, Ryota Shirai, Masanori Yoshida, Toru Uchiyama, Junko Nagasawa, Susumu Goyama, Takako Yoshioka, Daisuke Tomizawa, Mineo Kurokawa, Yoichi Matsubara, Nobutaka Kiyokawa, Kimikazu Matsumoto, Kenichiro Hata, Motohiro Kato

PEDIATRIC BLOOD & CANCER (2018)

Add to Collection

Letter Oncology

Successful treatment of systemic EBV positive T-cell lymphoma of childhood using the SMILE regimen

Masanori Yoshida, Tomoo Osumi, Ken-Ichi Imadome, Daisuke Tomizawa, Motohiro Kato, Noritaka Miyazawa, Reiko Ito, Atsuko Nakazawa, Kimikazu Matsumoto

PEDIATRIC HEMATOLOGY AND ONCOLOGY (2018)

Add to Collection

Review Pediatrics

Treatment and biology of pediatric acute lymphoblastic leukemia

Motohiro Kato, Atsushi Manabe

PEDIATRICS INTERNATIONAL (2018)

Add to Collection

Article Oncology

Integrated Molecular Characterization of the Lethal Pediatric Cancer Pancreatoblastoma

Tomoya Isobe, Masafumi Seki, Kenichi Yoshida, Masahiro Sekiguchi, Yusuke Shiozawa, Yuichi Shiraishi, Shunsuke Kimura, Misa Yoshida, Yoshikage Inoue, Akira Yokoyama, Nobuyuki Kakiuchi, Hiromichi Suzuki, Keisuke Kataoka, Yusuke Sato, Tomoko Kawai, Kenichi Chiba, Hiroko Tanaka, Teppei Shimamura, Motohiro Kato, Akihiro Iguchi, Asahito Hama, Tomoaki Taguchi, Masaharu Akiyama, Junya Fujimura, Akiko Inoue, Tsuyoshi Ito, Takao Deguchi, Chikako Kiyotani, Tomoko Iehara, Hajime Hosoi, Akira Oka, Masashi Sanada, Yukichi Tanaka, Kenichiro Hata, Satoru Miyano, Seishi Ogawa, Junko Takita

CANCER RESEARCH (2018)

Add to Collection

Article Oncology

Phase II/III study in children and adolescents with newly diagnosed B-cell precursor acute lymphoblastic leukemia: protocol for a nationwide multicenter trial in Japan

Katsuyoshi Koh, Motohiro Kato, Akiko M. Saito, Akiko Kada, Hirohide Kawasaki, Yasuhiro Okamoto, Toshihiko Imamura, Keizo Horibe, Atsushi Manabe

JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2018)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.